$TENX News

Tenax Therapeutics (NASDAQ:TENX) Q1 2026 Slightly Beats EPS, Gears Up for Pivotal Phase 3 Data in Q3

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tenax Therapeutics Q1 EPS $(0.35) Beats $(0.58) Estimate

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Appoints Thomas R. Staab II CFO Effective May 11, Replacing Interim CFO McGauley

Tenax Therapeutics Files Prospectus For Offering $300M Securities

Tenax Therapeutics: A Binary Bet With Heavy Downside Likely

Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35

Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $34

Tenax Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results.

Tenax Therapeutics: Q4 Earnings Snapshot

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics: A Speculative Buy